|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2011-5-20
|
|
pubmed:abstractText |
A new achiral class of N-hydroxyformamide inhibitor of both ADAM-TS4 and ADAM-TS5, 2 has been discovered through modification of the complex P1 group present in historical inhibitors 1. This structural change improved the DMPK properties and greatly simplified the synthesis whilst maintaining excellent cross-MMP selectivity profiles. Investigation of structure-activity and structure-property relationships in the P1 group resulted in both ADAM-TS4 selective and mixed ADAM-TS4/5 inhibitors. This led to the identification of a pre-clinical candidate with excellent bioavailability across three species and predicting once daily dosing kinetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:CummingJohn GJG,
pubmed-author:DaviesChrisC,
pubmed-author:De SaviChrisC,
pubmed-author:LamontScottS,
pubmed-author:MilneDavidD,
pubmed-author:MoorePeterP,
pubmed-author:PageKenK,
pubmed-author:PapeAndrewA,
pubmed-author:SawyerYvonneY,
pubmed-author:SmithPeter DPD,
pubmed-author:TartJonathonJ,
pubmed-author:TingAttillaA
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3301-6
|
|
pubmed:meshHeading |
pubmed-meshheading:21536437-ADAM Proteins,
pubmed-meshheading:21536437-Administration, Oral,
pubmed-meshheading:21536437-Animals,
pubmed-meshheading:21536437-Enzyme Inhibitors,
pubmed-meshheading:21536437-Formamides,
pubmed-meshheading:21536437-Humans,
pubmed-meshheading:21536437-Molecular Structure,
pubmed-meshheading:21536437-Osteoarthritis,
pubmed-meshheading:21536437-Procollagen N-Endopeptidase,
pubmed-meshheading:21536437-Stereoisomerism,
pubmed-meshheading:21536437-Structure-Activity Relationship,
pubmed-meshheading:21536437-Swine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.
|
|
pubmed:affiliation |
Respiratory and Inflammation Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. chris.desavi2@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article
|
